BioMedWorks’ Newsletter

BioMedWorks’ Newsletter

Share this post

BioMedWorks’ Newsletter
BioMedWorks’ Newsletter
NVS is using Molecular Partners' DARPins to make SARS-CoV-2 therapeutics

NVS is using Molecular Partners' DARPins to make SARS-CoV-2 therapeutics

What in the world are DARPins? PREMIUM CONTENT

BioMedWorks's avatar
BioMedWorks
Mar 15, 2021
∙ Paid
1

Share this post

BioMedWorks’ Newsletter
BioMedWorks’ Newsletter
NVS is using Molecular Partners' DARPins to make SARS-CoV-2 therapeutics
1
Share

DARPins are so cool, that I put them in the plot of my med thriller, Vampire Chimeras, back in 2013. (I also found out about and used CRISPR/cas in insects’ immunity, but that’s a story for another time.) In the novel, I used these protein scaffolds to make a vaccine to fight dengue fever. Now, lo and behold! IRL, Novartis/Molecular Partners collaboration is making an antiviral therapeutic — for SARS-CoV-2.

Ensovibep (MP0420) binding to COVID-19 spike protein. HSA = human serum albulmin

Keep reading with a 7-day free trial

Subscribe to BioMedWorks’ Newsletter to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 BioMedWorks LLC
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share